In this episode of “Moving Medicine Forward” – The Podcast, Lily McNally and Heidi Shenk from the American Brain Tumor Association (ABTA) share their personal connections to brain tumors and discuss the ABTA’s resources, research initiatives, and community partnerships. They also discuss ABTA’s “Meet Hope Head On” campaign to triple research funding and expand patient outreach. Tune in to learn how the ABTA is advancing brain tumor research and how you can get involved or donate: CTI Cares Employee Fund

0:23 Meet our guests from the American Brain Tumor Association (ABTA), Lily McNally and Heidi Shenk, who share their personal stories and connection to the organization.

0:52 Heidi discusses her personal experience with brain tumors and how it led her to become involved with the ABTA.

3:11 Lily shares her journey and how her family's experience with brain tumors inspired her to contribute to the mission of the ABTA.

4:33 Heidi and Lily talk about how their families became involved with the ABTA and its supportive community.

7:21 Learn about the various resources the ABTA offers to patients and families, and how these services have personally benefited Heidi and Lily. For help, call the ABTA Care Line: 800-886-ABTA(2282).

11:36 Heidi and Lily explain ABTA’s partnerships with marathons, including Cincinnati’s Flying Pig, and how local events support their mission.

13:47 Discover how physicians, alumni, and others can contribute to the ABTA’s efforts, including its annual national conference. [Learn more about the Alumni Research Network (AARN): ABTA Alumni Research Network - Learn More or Donate Today!]

15:43 The ABTA’s 5-year campaign, Meet Hope Head On, aims to triple research funding, double patient outreach, and increase federal funding for oncology research. [Link to donate: CTI Cares Employee Fund]

17:15 Discover how the ABTA partners with clinical research organizations like CTI to help patients access clinical trials and advance treatment options. [Link to Clinical Trial Finder: Home | ClinicalTrials.gov]

19:45 In August 2024, the FDA approved a new treatment for low-grade glioblastomas. [Get the latest information on this treatment: VORANIGO® (vorasidenib) | For Grade 2 IDH-Mutant Glioma]

In this episode of "Moving Medicine Forward" - The Podcast, Greg Ruf, Founder & Executive Director of the DCM Foundation, and Bret Marshall, Senior Director of Business Development & Client Management at CTI, discuss the vital role of patient advocacy groups and the partnership between CTI and the DCM Foundation. Greg shares his journey in founding the DCM Foundation, and they explore key projects, achievements, and strategies for patient education and sponsor engagement. Tune in to learn how collaboration can enhance clinical research and advance patient advocacy.

0:24 Introduction of guests Greg Ruf and Bret Marshall.

1:06 Explanation of patient advocacy groups.

2:30 Overview of CTI and DCM Foundation partnership.

3:22 Greg’s journey in founding the DCM Foundation.

4:41 CTI's criteria for selecting advocacy group partners.

6:30 Highlights of joint projects and initiatives with DCM Foundation.

8:33 Key achievements of the DCM Foundation.

13:28 Methods used by the DCM Foundation to educate patients.

18:20 Ways for listeners to contribute.

23:16 Discussion on the timing of genetic testing.

25:40 Strategies to engage sponsors with advocacy groups.

28:36 How the DCM Foundation connects with patients.

34:42 Advice for enhancing collaboration between CROs, pharma, and advocacy groups.

In this special 25th-anniversary episode of "Moving Medicine Forward" - The Podcast, we're excited to welcome Tim Schroeder, Chief Executive Officer of CTI, Lynn Fallon, CTI Board Member and former President, and Kevin Schwarz, Chief Operating Officer of CTI. They share insights into CTI’s founding vision and its evolution over the past quarter-century. Tim and Kevin also discuss how CTI has driven innovation and contributed to the growth of the clinical research industry, highlighting key milestones such as their involvement in over 200 drug approvals. Join us as we celebrate this milestone and explore CTI's journey!